LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 4 of total 4

Search options

  1. Article ; Online: Evaluation of urine SARS-COV-2 RT-PCR as a predictor of acute kidney injury and disease severity in patients with critical COVID-19.

    de Souza, Sérgio Pinto / Silveira, Marcelo Augusto Duarte / Souza, Bruno Solano de Freitas / Cabral, Julia Barros / de Melo, Erica Batista Dos Santos Galvão / Nonaka, Carolina Kymie Vasques / Coelho, Fernanda Oliveira / da Hora Passos, Rogério

    The Journal of international medical research

    2021  Volume 49, Issue 5, Page(s) 3000605211015555

    Abstract: Coronavirus disease 2019 (COVID-19) is an emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which began as an outbreak in Wuhan, China and has spread rapidly across the globe. Although most infections are ...

    Abstract Coronavirus disease 2019 (COVID-19) is an emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which began as an outbreak in Wuhan, China and has spread rapidly across the globe. Although most infections are mild, patients with severe and critical COVID-19 infections face deterioration of respiratory function and may also have extrapulmonary manifestations, mostly affecting the kidney, digestive tract, heart, and nervous system. Here, we prospectively evaluated the presence of SARS-CoV-2 genetic material using reverse-transcription polymerase chain reaction in urine samples obtained from patients with COVID-19 receiving critical care. Among 51 included patients, we found higher serum creatinine levels, a longer hospital stay, and more frequent need for dialysis in urine-positive patients. These findings could suggest that, in predisposed patients, a direct viral cytopathic effect may contribute to a more severe disease phenotype.
    MeSH term(s) Acute Kidney Injury/diagnosis ; Acute Kidney Injury/genetics ; COVID-19 ; China/epidemiology ; Humans ; Reverse Transcriptase Polymerase Chain Reaction ; SARS-CoV-2 ; Severity of Illness Index
    Language English
    Publishing date 2021-05-14
    Publishing country England
    Document type Journal Article
    ZDB-ID 184023-x
    ISSN 1473-2300 ; 0300-0605 ; 0142-2596
    ISSN (online) 1473-2300
    ISSN 0300-0605 ; 0142-2596
    DOI 10.1177/03000605211015555
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 925: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Standardized Brazilian green propolis extract (EPP-AF®) in COVID-19 outcomes: a randomized double-blind placebo-controlled trial.

    Silveira, Marcelo Augusto Duarte / Menezes, Matheus de Alencar / de Souza, Sergio Pinto / Galvão, Erica Batista Dos Santos / Berretta, Andresa Aparecida / Caldas, Juliana / Teixeira, Maurício Brito / Gomes, Marcel Miranda Dantas / Damiani, Lucas Petri / Bahiense, Bruno Andrade / Cabral, Julia Barros / De Oliveira, Cicero Wandson Luiz Macedo / Mascarenhas, Talita Rocha / Pinheiro, Priscila Carvalho Guedes / Alves, Milena Souza / de Melo, Rodrigo Morel Vieira / Leite, Flávia Mendes / Nonaka, Carolina Kymie Vasques / Souza, Bruno Solano de Freitas /
    Baptista, Nathália Ursoli / Teles, Flávio / da Guarda, Suzete Farias / Mendes, Ana Verena Almeida / Passos, Rogério da Hora

    Scientific reports

    2023  Volume 13, Issue 1, Page(s) 18405

    Abstract: SARS-CoV-2 and its different variants caused a "wave and wave" pandemic pattern. During the first wave we demonstrated that standardized Brazilian green propolis extract (EPP-AF®) reduces length of hospital stay in adult patients with COVID-19. ... ...

    Abstract SARS-CoV-2 and its different variants caused a "wave and wave" pandemic pattern. During the first wave we demonstrated that standardized Brazilian green propolis extract (EPP-AF®) reduces length of hospital stay in adult patients with COVID-19. Afterwards, we decided to evaluate the impact of EPP-AF in hospitalized patients during the third wave of the pandemic. BeeCovid2 was a randomized, double-blind, placebo-controlled clinical trial in hospitalized COVID-19 adult patients. Patients were allocated to receive an oral dose of 900 mg/day of EPP-AF® or placebo for 10 days. The primary outcome was length of hospital stay. Secondary outcomes included safety, secondary infection rate, duration of oxygen therapy dependency, acute kidney injury and need for intensive care. Patients were followed up for 28 days after admission. We enrolled 188 patients; 98 were assigned to the propolis group and 90 to the placebo group. The post-intervention length of hospital stay was of 6.5 ± 6.0 days in the propolis group versus 7.7 ± 7.1 days in the control group (95% CI - 0.74 [- 1.94 to 0.42]; p = 0.22). Propolis did not have significant impact on the need for oxygen supplementation or frequency of AKI. There was a significant difference in the incidence of secondary infection between groups, with 6.1% in the propolis group versus 18.9% in the control group (95% CI - 0.28 [0.1-0.76], p = 0.01). The use of EPP-AF was considered safe and associated with a decrease in secondary infections. The drug was not associated with a significant reduction in length of hospital stay. ClinicalTrials.gov (NCT04800224).
    MeSH term(s) Adult ; Humans ; COVID-19/epidemiology ; SARS-CoV-2 ; Propolis/therapeutic use ; Brazil/epidemiology ; Coinfection/drug therapy ; Double-Blind Method ; Treatment Outcome
    Chemical Substances Propolis (9009-62-5)
    Language English
    Publishing date 2023-10-27
    Publishing country England
    Document type Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2615211-3
    ISSN 2045-2322 ; 2045-2322
    ISSN (online) 2045-2322
    ISSN 2045-2322
    DOI 10.1038/s41598-023-43764-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Evaluation of Urine SARS-COV-2 RT-PCR as a predictor of Acute Kidney Injury and disease severity in critical COVID-19 patients

    de Souza, Sergio Pinto / Silveira, Marcelo Augusto Duarte / Souza, Bruno Solano de Freitas / Nonaka, Carolina Kymie Vasques / de Melo, Erica / Cabral, Julia Barros / Coelho, Fernanda / Passos, Rogerio da Hora

    medRxiv

    Abstract: The novel coronavirus disease (COVID-19) is an emerging infectious disease caused by SARS-CoV-2, which began as an outbreak in Wuhan, China and spread rapidly throughout the globe. Although the majority of infections are mild, severe and critical COVID- ... ...

    Abstract The novel coronavirus disease (COVID-19) is an emerging infectious disease caused by SARS-CoV-2, which began as an outbreak in Wuhan, China and spread rapidly throughout the globe. Although the majority of infections are mild, severe and critical COVID-19 patients face deterioration of respiratory function, and may also present extrapulmonary manifestations, mostly affecting the kidney, digestive tract, heart and nervous system. Here, we prospectively evaluated the presence of SARS-CoV-2 genetic material by RT-PCR in urine samples obtained from critical care COVID-19 patients. In 51 patients included, we found higher serum creatinine levels, a longer hospital stay and a more frequent dialysis need in urine-positive patients. These findings could suggest that, in predisposed patients, a direct viral cytopathic effect may contribute to a more severe disease phenotype
    Keywords covid19
    Language English
    Publishing date 2021-01-15
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.01.13.21249576
    Database COVID19

    Full text online

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: The use of standardized Brazilian green propolis extract (EPP-AF) as an adjunct treatment for hospitalized COVID-19 patients (BeeCovid2): a structured summary of a study protocol for a randomized controlled trial.

    Silveira, Marcelo Augusto Duarte / de Souza, Sergio Pinto / Dos Santos Galvão, Erica Batista / Teixeira, Maurício Brito / Gomes, Marcel Miranda Dantas / Damiani, Lucas Petri / Bahiense, Bruno Andrade / Cabral, Julia Barros / De Oliveira, Cicero Wandson Luiz Macedo / Mascarenhas, Talita Rocha / Pinheiro, Priscila Carvalho Guedes / Alves, Milena Souza / de Melo, Rodrigo Morel Vieira / Berretta, Andresa Aparecida / Leite, Flávia Mendes / Nonaka, Carolina Kymie Vasques / de Freitas Souza, Bruno Solano / Mendes, Ana Verena Almeida / da Guarda, Suzete Farias /
    da Hora Passos, Rogério

    Trials

    2022  Volume 23, Issue 1, Page(s) 255

    Abstract: Background: The 2019 coronavirus disease (COVID-19) pandemic continues to spread and affects large numbers of people with unprecedented impacts. Experimental evidence has already been obtained for use of the standardized extract of Brazilian green ... ...

    Abstract Background: The 2019 coronavirus disease (COVID-19) pandemic continues to spread and affects large numbers of people with unprecedented impacts. Experimental evidence has already been obtained for use of the standardized extract of Brazilian green propolis (EPP-AF) against viral targets, and clinical rationality has been demonstrated for testing this extract as an adjunct to treatment in patients affected by COVID-19. The BeeCovid2 study aims to assess whether EPP-AF has an impact on the improvement of patients hospitalized with COVID-19 by reducing the length of hospital stay.
    Methods: BeeCovid2 is a randomized, double-blinded, placebo-controlled clinical study being conducted in Brazil to provide further evidence on the effectiveness of standardized green propolis extract as an adjunctive treatment for adults hospitalized with COVID-19. Hospitalized patients over 18 years of age with a confirmed diagnosis of COVID-19 and up to 14 days of symptoms were included. Patients under mechanical ventilation at randomization, pregnant women, cancer patients, transplanted or using immunosuppression, HIV patients, patients who used propolis in the last 30 days, bacterial or fungal infection at randomization, impossibility of using medication orally or enterally, and advanced chronic diseases (e.g., advanced heart failure, severe liver disease, and end-stage chronic kidney disease). Enrolled patients are randomized at a 1:1 ratio to receive placebo or standardized propolis extract (900 mg/day) for 10 days. The study treatments are administered in a double-blinded manner, and patients are followed for 28 days. The primary outcome is the difference in length of hospital stay in days between groups. Secondary outcomes include the need for mechanical ventilation, the rate of secondary infection, rate of acute kidney injury, the need for renal replacement therapy, the requirement for vasoactive drugs, the use of an intra-aortic balloon pump (IABP), and the use of extracorporeal membrane oxygenation (ECMO).
    Discussion: This trial is very useful and will provide more data on the effectiveness of using the standardized Brazilian green propolis extract as an adjunctive treatment in association with standard care in adults hospitalized with moderate to severe acute COVID-19.
    Trial registration: ClinicalTrials.gov NCT04800224 . Registered on March 16, 2021.
    MeSH term(s) Adolescent ; Adult ; Brazil ; Female ; HIV Infections/drug therapy ; Humans ; Plant Extracts ; Pregnancy ; Propolis/adverse effects ; Randomized Controlled Trials as Topic ; COVID-19 Drug Treatment
    Chemical Substances Plant Extracts ; Propolis (9009-62-5)
    Language English
    Publishing date 2022-04-04
    Publishing country England
    Document type Clinical Trial Protocol ; Journal Article
    ZDB-ID 2040523-6
    ISSN 1745-6215 ; 1468-6694 ; 1745-6215
    ISSN (online) 1745-6215
    ISSN 1468-6694 ; 1745-6215
    DOI 10.1186/s13063-022-06176-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top